Vitamin D is a New Promising Inhibitor to the Main Protease (Mpro) of COVID-19 by Molecular Docking

Ghassab M. Al-Mazaideh¹, Mohammed H. Shalayel², Farhan K. Al-Swailmi² and Saleem H. Aladaileh²

¹Department of Pharmaceutical Chemistry, College of Pharmacy, University of Hafr Al-Batin, Hafr Al-Batin, Saudi Arabia.
²Department of Pharmacy Practice, College of Pharmacy, University of Hafr Al-Batin, Hafr Al-Batin, Saudi Arabia.

Authors’ contributions
This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information
DOI: 10.9734/JPRI/2021/v33i29B31603

Received 20 March 2021
Accepted 25 May 2021
Published 26 May 2021

ABSTRACT

In this study, vitamin D has shown greater efficacy of binding with M\textsuperscript{pro} of COVID-19 compared to the recently recommended drugs. The docking study was simulated to streamline interaction effects of Vitamin D, Remdesivir, Chloroquine, Hydroxychloroquine, Aspirin, and Azithromycin complexes with the active site of M\textsuperscript{pro}. Vitamin D is found to have the highest potential interaction in terms of total H-bond, van der Waal, torsional, and desolvation energy which were the lowest among all the selected drugs. The hydroxyl group of vitamin D and the thiol group of M\textsuperscript{pro} cysteine had played a leading role in increasing Vitamin D binding and stability with the M\textsuperscript{pro} pocket by contribution to the inception of three hydrogen bonds. The study recommend that vitamin D can be added to the COVID-19 treatment protocol, which may have the desired effect on viral replication inhibition and decreases mortality.

*Corresponding author: E-mail: gmazaideh@uhb.edu.sa;
1. INTRODUCTION

The world is now grappling with time to overcome the fight against COVID-19, which has no accepted treatment or procedure to deal with until now [1]. Despite being pronounced by WHO as a global pandemic disease, there are no absolutely approved vaccines and specific antiviral medications salutary to prohibit this viral infection. Hence, there is a great need to utilize some new compounds as potential antiviral candidates [2].

Clinical data had displayed that vitamin D has a preventative impact against respiratory tract infections, and meta-analyses corroborated the correlation between the incidence of influenza and low 25(OH)D levels [10,11]. It is progressively realized that localized formation of vitamin D is accountable for numerous immune effects in respiratory diseases and may help in restraining SARS-CoV-2 infection [12,13].

In our previous in silico study, Vitamin D displayed, with respect to lower binding energy (LBE), the strongest interaction against the virtual binding sites of the Nsp15 of COVID-19 compared with the other drugs utilized for treatment of COVID-19 [14].

This research aimed to study the binding interaction of Vitamin D with the main protease (Mpro), which plays a key role in COVID-19 replication and compare that to the lately proposed drugs in COVID-19 treatment, such as Remdesivir, Chloroquine, Hydroxychloroquine, Aspirin, and Azithromycin.

2. METHODOLOGY

The X-ray crystal structure of the main protease was downloaded from the RCSB database (PDB ID: 6LU7) [15]. Biovia Discovery Studio Visualizer 16.1 was utilized to remove the heteroatoms, water, and prepare the protein further. The 2D chemical structures of Vitamin D and the supposed drugs (Remdesivir, Chloroquine, Hydroxychloroquine, Aspirin, and Azithromycin) were uploaded from the PubChem database. Then, PerkinElmer Chem3D 17.1 software was used to implement the MM2 force field at the ligands, and finally saved as PDB format.

AutoDock 4.2 is a computational software used to prepare the ligands and protein, as well as to

Keywords: Molecular docking; vitamin D; Mpro; COVID-19; thiol group.
generate the docking process [16]. A click-by-click protocol was used to enforce this process [17]. Initially, the polar hydrogens and Kollman charge were added to the main protease. Then, we revitalized the selected drugs by Gasteiger charges. The size of the grid box was set to 50*50*50, and the coordinates were -10.244, 17.966, 66.508 (as x, y, z respectively) with spacing 0.375. For the docking parameter, the Mpro was defined as rigid and drugs are flexible. The genetics algorithm run was set to 150, and the Lamarckian genetic was selection to proceed the docking, while the remaining parameters were kept default [17].

3. RESULT

3.1 Molecular Docking with Mpro

Vitamin D, Remdesivir, Chloroquine, Hydroxychloroquine, Aspirin, and Azithromycin were docked to Mpro. The predicted free binding energy (F.B.E), inhibition constant (Ki), van der Waals and H-bond desolvation energy, final intermolecular energy, torsional free energy, and unbound energy of Vitamin D and the selected drugs were given in Table 1.

As expected, all the selected ligands entered Mpro pocket and were possess varying scores with the enclosed amino acids according to the determined coordinates. Remarkably from Table 1, Vitamin D overtook the rest drugs, by forming a strong interaction with the protease (-7.26 kcal/mol). Followed by the presence of Chloroquine, Remdesivir, Aspirin and Hydroxychloroquine close to each other inside the Mpro binding site. Obviously, the affinity of binding of the azithromycin was the least of all selected drugs. Also found the total H-bond, van der Waal, and the desolvation energy for vitamin D was the lowest. Then pursued by Remdesivir, Azithromycin, Hydroxychloroquine, Chloroquine, and Aspirin. The findings too showed that the torsional energy between vitamin D and Mpro was mostly the least of all. The best score of the selected drugs (Vitamin D) was analyzed using complex Biovia Discovery Visualizer 16.1, LigPlot+ 2.1, and LigandScout 4.3 as presented in Fig. 1.

The hydroxyl group of vitamin D and the thiol group of Mpro cysteine had played a leading role in increasing Vitamin D binding and stability with the main protease pocket by being contributed to the inception of three hydrogen bonds. Two H-bond donors forming one pairing H-bonds with the oxygen atom coded OG1 in THR24 and THR25 THR24, THR25 at distance 2.90 Å, and 2.75 Å respectively. And the third H-bond was acceptor from the oxygen atom (OG1) of THR45 with length 2.94 Å.

![Fig. 1. 2D and 3D interactions models of Vitamin D complex with the active binding site of Mpro. (a and b) were generated by using BIOVIA Discovery Studio visualizer 16.1. (c and d) by LigandScout 4.3. And (e) by LigPlot+2.1](image-url)
4. DISCUSSION

Presently, Coronavirus has turn out to be a major challenge for all the world. The outbreak of this particular virus is disseminating worldwide and leading to sundry mortalities. Nevertheless, simply no drugs are efficient for the avoidance of this pandemic. Thus, many researchers tried to find some natural products that might be useful to halt the spread of Coronavirus and simultaneously consolidate immunity [2]. So far, the broad-spectrum antiviral drugs including Chloroquine and Remdesivir are being in vitro utilized to beat SARS-CoV-2 [18]. Beating MPro could be efficacious as it might cease the replication of SARS-CoV-2 RNA whereas suppressing NSP15 may bring into some structural changes which may never allow this virus to invade the particular host cells [19,20]. MPro is a sound drug target for the virus as it plays an indispensable role in the typical viral replication and transcription. With this regard many in silico studies were conducted to show and evaluate the efficacy of some active ingredients like flavonoids and some other natural products against SARS-CoV-2 MPro utilizing molecular docking technique. Taking in consideration the relative safe profile of these natural ingredients, these compounds could be be held in future as an outset for new therapeutics against COVID-19 [6,21]. In our previous study on the efficacy of vitamin D as is a potential inhibitor of SARS-CoV-2 endoribonuclease Nsp15, we found that Vitamin D is uniquely suppressed the three active sites in Nsp15 with significant advantageousness when compared to the other drugs utilized in treatment of COVID-19 like Remdesivir, Chloroquine, and Hydroxychloroquine [20].

Meanwhile, MET49 amino acid created a map of hydrophobic interactions with hexane ring and vitamin D alkyl chain that increased stability.

Table 1. Free Binding Energy (F.B.E), inhibition constant (Ki), van der Waals and H-bond desolvation energy, electrostatic energy, and torsional free energy of all the chosen drugs with MPro

| Compound      | F.B.E (kcal/mole) | Ki (uM) | vDW + Hbond + desolv Energy (kcal/mole) | Electrostatic Energy (kcal/mole) | Torsional Free Energy (kcal/mole) |
|---------------|-------------------|---------|----------------------------------------|---------------------------------|----------------------------------|
| Remdesivir    | -4.59             | 431.87  | -9.06                                  | -0.01                           | +5.07                            |
| Chloroquine   | -4.68             | 373.83  | -6.92                                  | -0.14                           | +2.39                            |
| Hydroxychloroquine | -4.22         | 812.81  | -7.06                                  | -0.14                           | +2.98                            |
| Vitamin D     | -7.26             | 4.76    | -9.89                                  | -0.06                           | +2.09                            |
| Aspirin       | -4.46             | 533.64  | -5.60                                  | -0.06                           | +1.19                            |
| Azithromycin  | -2.61             | 12.24   | -8.70                                  | -2.70                           | +8.35                            |

MPro is a 33.8 kDa protein with 306 amino acid moieties that constituting three domains and COVID-19 virus Mpro comprises cysteine–histidine catalytic site and the active site of MPro is composed of four sites (S10, S1, S2, and S4) that is quietly kept conserved in all the coronaviruses main protease. It has been formerly adduced that the substrate-binding site of SARS-CoV-2 Mpro is located in the cleft between Domain-I and II, and the 1 to 7 N-terminal amino acids residues are implicated in the proteolytic action. The C terminal domain III is typically globular cluster of 5 helices that regulates the salt-bridge interceded dimerization of MPro. To maintain antiviral activity, the SH group of cysteine found in the S10 site readily anchors inhibitors [22,6]. It seems that the presence of thiol group found in cysteine moiety that anchors inhibitors of MPro is fundamental for binding vitamin D to the binding site of the main protease since, cysteine is a main component of vitamin D binding proteins and vitamin D by itself inhibit cysteine proteases [23,24]. Continuously never before, in this research, a number of recently proposed drugs for the treatment of COVID-19 and vitamin D have been implemented to study their effect with the main protease binding site. The findings of the present study have shown that vitamin D was the best in forming bonds and can be used as a main or in combination with other drugs against COVID-19.

5. CONCLUSION

The results showed that vitamin D was highly capable of combining with MPro, and the torsional energy was the lowest among the drugs chosen in this study. The hydroxyl group of vitamin D and the thiol group of MPro cysteine had played a leading role in increasing Vitamin D binding and stability with the main protease pocket by being
contributed to the inception of three hydrogen bonds. The addition of Vitamin D to the COVID-19 treatment protocol may have a desired effect on the viral replication inhibition, enhancing immunity and reduce the mortality rate. To evaluate these core observations and understand the action of vitamin D, we highly recommend testing Vitamin D with COVID-19 in laboratory studies and in vivo assay.

CONSENT

It’s not applicable.

ETHICAL APPROVAL

It’s not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Roosa K, Lee Y, Kirpich A, Rothenberg R, Hyman JM, Yan P, Chowell G. Real-time forecasts of the COVID-19 epidemic in China from February 5th to February 24th, 2020. Infect. Disease Mod. 2020;5:256-263.

2. Joshi T, Joshi T, Sharma P, Mathpal S, Pandit H, Bhatt V, Chandra S. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking. Eur. Rev. Med. Pharmacol. Sci. 2020;24(8):4529-4536.

3. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020;368:409-412.

4. Narkhede RR, Pise AV, Cheke RS, Cheke RS, Shinde SD. Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences. Nat. Prod. Bioprospect. 2020;10:297-306. Available: https://doi.org/10.1007/s13659-020-00253-1.

5. Baez-Santos YM, St John SE and Mesecar AD. The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antivir. Res. 2015;115:21-38.

6. Motiwale M, Yadav NS, Kumar S, Kushwaha T, Choudhir G, Sharma S, Singour KP. Finding potent inhibitors for COVID-19 main protease (Mpro): an in silico approach using SARS-CoV-3CL protease inhibitors for combating CORONA. J. Biomol. Struct. Dyn. 2020;8:1-12. DOI: 10.1080/07391102.2020.1829501.

7. Jung SM, Akhmetzhanov AR, Hayashi K, Linton NM, Yang Y, Yuan B, Kobayashi T, Kinoshita R and Nishiura H. Real-Time Estimation of the Risk of Death from Novel Coronavirus (COVID-19) Infection: Inference Using Exported Cases. J. Clin. Med. 2020;9(2):523.

8. Broojmans N, Kuntz ID. Molecular recognition and docking algorithms. Annual Rev. Biophys. Biomol. Struct. 2003;32(1):335-373.

9. Lybrand TP. Ligand—protein docking and rational drug design. Curr. Opin. Struct. Biol. 1995. 5(2):224-228.

10. Martineau AR, Jolliffe DA, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Gammaa D, Ginde AA, Goodall EC, Grant CC, Janssens W, Jensen ME, Kerley CP, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, Rees JR, Simpson S, Stelmach I, Trilok Kumar G, Urashima M, Camargo CA, Griffiths CJ and Hooper RL. Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis. Health Technol. Assess. 2019;23(2):1-44. DOI: 10.3310/hta23020. PMCID: 30675873. DOI: 10.3310/hta23020.

11. Shalayel MH, Al-Qahtani AM, Hunefi MA. Vitamin D or flu vaccine-benefits over adverse effects. Br. Biomed Bull. 2018;6:311.

12. Hansdottir S, Monick MM. Vitamin D effects on lung immunity and respiratory diseases. Vitam. Horm. 2011;86:217-37.

13. Xu Y, Baylink DJ, Chen CS, Reeves ME, Xiao J, Lacy C, Lau E, Cao H. The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19. J. Transl. Med. 2020;18:322. Available: https://doi.org/10.1186/s12967-020-02488-5.

14. Shalayel MH, Al-Mazaideh GM, Aladaileh SH, Al-Swailm FK and Al-Thiaba MG. Vitamin D is a potential inhibitor of COVID-19: In silico molecular docking to the binding site of SARS-CoV-2 endoribonuclease Nsp15. Pak. J. Pharm. Sci. 2020;33(5):2179-2186.
Jin Z, Du X, Yechun Xu, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, Duan Y, Yu J, Wang L, Yang K, Liu F, Jiang R, Yang X, You T, Liu X, Yang X, Bai F, Liu H, Liu X, Guddat LW, Xu W, Xiao G, Qin C, Shi Z, Jiang H, Rao Z, Yang H. Structure of M\textsuperscript{pro} from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;1-5.

Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand docking and virtual drug screening with the Auto Dock suite. Nat. Protoc. 2016;11(5):905-19. DOI: 10.1038/nprot.2016.051.

Rizvi SMD, Shakil S, Haneef M. A simple click by click protocol to perform docking: Auto Dock 4.2 made easy for non-bioinformaticians. EXCLI J. 2013;12:831.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271.

Zhang J, Shen X, Yan Y, Wang Y, Cheng Y. Discovery of anti-SARS-CoV-2 agents from commercially available flavor via docking screening. OSF Preprints; 2020.

Yang H, Xie W, Xue X, Yang K, Ma J, Liang W, Zhao Q, Zhou Z, Pei D, Ziebuhr J, Hilgenfeld R, Yuen KY, Wong L, Gao G, Chen S, Chen Z, Ma D, Bartlam M, Rao Z. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005;3(10):e324.

Larriba MJ, García de Herreros A and Muñoz A. Vitamin D and the Epithelial to Mesenchymal Transition. Stem Cells Inter; 2016. Article ID: 6213872. Available:https://doi.org/10.1155/2016/6213872.

Bikle DD. Vitamin D metabolism, mechanism of action and clinical applications. Chem. Biol. 2014;21(3):319-329. DOI: 10.1016/j.chembiol.2013.12.016.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/68656